Summit Therapeutics, a US biopharma company with a focus in oncology, has announced a collaboration with Pfizer to assess Ivonescimab through clinical trials.

Ivonescimab is a novel, investigational PD-1 / VEGF bispecific antibody. The companies will utilise many of Pfizer’s antibody drug conjugates (ADCs) across several solid tumour situations. The project aims to enhance the advancement of such treatments and improve patient care standards. Each of these studies will involve ivonescimab plus one of Pfizer’s vedotin ADCs in individual, distinct solid tumour sites to establish the safety efficacy and which combinations relate to anti-tumour effects. The first of these studies is due to begin in the middle of this year, combining the bispecific antibody candidate with Pfizer’s vedotin ADCs. The studies will be overseen by both parties, with Summit will providing ivonescimab and Pfizer responsible for handling the operations of the trials. Both companies will retain the rights to their respective products.